Summary

Eligibility
for people ages 6-17 (full criteria)
Location
at UC Davis
Dates
study started
completion around

Description

Summary

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).

Official Title

Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age

Keywords

Acute Treatment of Migraine, Long-term safety, acute treatment, migraine, phonophobia, photophobia, nausea, pediatric, children, adolescent, Migraine Disorders, Rimegepant (PF-07899801)

Eligibility

Locations

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Pfizer
Links
To obtain contact information for a study center near you, click here.
ID
NCT04743141
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 200 study participants
Last Updated